Hepatoprotective Natural Products

Omayma A. Eldahshan *  
Pharmacognosy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

ABSTRACT

Egypt holds a unique position in the epidemiology of liver diseases and cancer. We, here, shed the light on some important plant extracts and pure compounds that could be used as a new building unit for treatment of liver diseases.

Keywords: Hepatoprotective; Natural Products.

1. INTRODUCTION

Hepatotoxins as chemicals, pharmaceutical drugs, alcohols, pollutants, hepatitis viral infection or even some medicinal plants are responsible for hepatotoxicity [1]. Annually, about more than two million people in the world die from liver-related disorders [2]. Nature is fighting liver disorders by their plant extracts and/or phytochemicals. This mini-review displays the potentials of some extracts as well as pure constituents as hepatoprotector.

2. Acrocarpus fraxinifolius

Alcoholic extract of Acrocarpus fraxinifolius (Fabaceae) could ameliorate hepatic injuries induced by γ-irradiation and CCl4 in rats suggesting potent hepatoprotective activity. In vivo, it reduced interleukin-6, TNF-a, nitric oxide, malondialdehyde, and DNA fragmentation and caspase-3 activity. It downregulated its m-RNA level and decreased proapoptotic protein Bax expression. In addition, the extract enhanced superoxide dismutase, glutathione peroxidase, catalase activities. It reduced glutathione concentrations and up-regulated the expression of antiapoptotic Bcl-2 [3]. Its hexane extract significantly alleviated the liver relative weight and biomarkers (serum aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase), lipid and bilirubin profiles and hepatic lipid peroxidation. It also increased body weight, serum protein profile and hepatic antioxidant capacity in paracetamol-induced hepatotoxicity in rats [4].

3. Lygodium microphyllum

Lygodium microphyllum (Cav.) R.Br. (Lygodiaceae) leaves aqueous extract could exert hepatoprotection that could be attributed to its antioxidative effects through protection of ultrastructural organelles. The extract was able to prevent the increase in levels of serum ALT, AST and hepatic malondialdehyde formation in a dose-dependent manner. Immunohistochemical results proved the suppression of oxidative stress markers as 4-hydroxynonenal, 8-
hydroxydeoxyguanosine, and pro-inflammatory cytokines as TNF-a, IL-6, PG-E2 [5].

4. Panax quinquefolius

Panax quinquefolius saponin exerts a protective effect against acetaminophen-induced hepatic injury because of its antioxidant, anti-apoptotic, and anti-inflammatory activities. Pretreatment with Panax quinquefolius saponin (ginsenoside) significantly decreased serum ALT, AST, TNF-α, and IL-1β levels in a dose-dependent manner as compared to the acetaminophen administration. In addition, it decreased hepatic malondialdehyde contents and 4-hydroxynonenal expression and restored reduced glutathione content and superoxide dismutase activity in livers of mice. It inhibited the overexpression of cyclooxygenase-2 and inducible nitric oxide synthase in the liver cells. The extract pretreatment inhibited the activation of apoptotic signaling pathways (through the increase of Bcl-2 and decrease of Bax and caspase-3 protein expression levels) [6].

5. Apigenin

Apigenin is found in many medicinal plants. After its oral administration, the levels of serum ALT and AST were decreased. Apigenin pretreatment increased the levels of the following: hepatic nuclear factor, erythroid 2-related factor 2, superoxide dismutase, catalase, glutathione S-transferase, and glutathione reductase activities. At the same time, it decreased the levels of tumor necrosis factor-α and hepatic nuclear factor-κB protein expression. These findings demonstrated that apigenin could prevent the D-GalN/LPS-induced liver injury in mice, and its mechanisms might be associated with the increments of Nrf-2-mediated antioxidative enzymes and modulation of PPARγ/NF-κB-mediated inflammation [7].

6. Conclusion

This mini-article provided evidence that nature is full of miracles that produce many potential hepatoprotectors. However, they must be evaluated later in pre-clinical and clinical assays to determine their safety and their preventive capacity to build a new block in liver drug discovery.

6. References